Ipca Laboratories Q2 FY'27 Earnings Call Summary
Ipca Laboratories Ltd · Transcript · 06 Nov 2026, 11:01 pm
Ipca Laboratories Q2 FY'27 Earnings Call Summary Ipca Laboratories reported 14% YoY consolidated revenue growth to INR2,910 crore in Q2 FY'27, with EBITDA margins expanding to 22.97% from 21.68%. Domestic formulations grew 14% YoY to INR1,157 crore, driven by Zerodol umbrella sales surpassing INR1,500 crore. Standalone export formulations rose 32% YoY to INR653 crore, supported by strong generic demand across Europe, Canada, and South Africa. Management maintained FY'27 revenue growth guidance at 14–16% with EBITDA margins of 22–23%, aiming for 100–125 bps annual margin expansion. The balance sheet remains virtually debt-free with ~INR700 crore cash.
Original exchange filing (PDF)
More announcements from Ipca Laboratories Ltd
- Audio Link of Conference Call held on 05.11.2026 · 05 Nov 2026
- Standalone and Consolidated Financial Results for second quarter and half year ended 30.09.2026 · 05 Nov 2026
- Standalone and Consolidated Financial Results for second quarter and half year ended 30.09.2026 · 05 Nov 2026
- Schedule of Conference Call · 05 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 05 Nov 2026
- Ipca Laboratories Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 05 Nov 2026
- Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Standalone and Consolidated .... · 05 Nov 2026
- Transcript of Conference Call · 17 Aug 2026
